| 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
alpha-Naphthylamine | 
CAS 134-32-7 | ||
C10H7NH2 | 
RTECS QM1400000 | ||
| 
Synonyms & Trade Names  1-Aminonaphthalene, 1-Naphthylamine  | 
DOT ID & Guide  2077 153  | 
||
Exposure
 | 
NIOSH REL: Ca See Appendix A | ||
| OSHA PEL: [1910.1004] See Appendix B | |||
| IDLH Ca [N.D.] See: IDLH INDEX | Conversion | ||
| 
Physical Description  Colorless crystals with an ammonia-like odor. [Note: Darkens in air to a reddish-purple color.]  | 
|||
| 
MW: 143.2 | 
BP: 573°F | 
MLT: 122°F | 
Sol: 0.002% | 
| 
VP(220°F): 1 mmHg | 
IP: 7.30 eV | 
 | 
Sp.Gr: 1.12 | 
| 
Fl.P: 315°F | 
UEL: ? | 
LEL: ? | 
 | 
| Combustible Solid | |||
| 
Incompatibilities & Reactivities  Oxidizes in air  | 
|||
| 
Measurement Methods  NIOSH 5518; OSHA 93 See: NMAM or OSHA Methods  | 
| 
Personal Protection & Sanitation (See protection)  Skin: Prevent skin contact Eyes: Prevent eye contact Wash skin: When contaminated/Daily Remove: When wet or contaminated Change: Daily Provide: Eyewash, Quick drench  | 
First Aid (See procedures)  Eye: Irrigate immediately Skin: Soap wash immediately Breathing: Respiratory support Swallow: Medical attention immediately  | 
| 
Important additional information about respirator selection Respirator Recommendations (See Appendix E) NIOSH At concentrations above the NIOSH REL, or where there is no REL, at any detectable concentration: (APF = 10,000) Any self-contained breathing apparatus that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode (APF = 10,000) Any supplied-air respirator that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary self-contained positive-pressure breathing apparatus Escape: (APF = 50) Any air-purifying, full-facepiece respirator with an N100, R100, or P100 filter. Click here for information on selection of N, R, or P filters./Any appropriate escape-type, self-contained breathing apparatus  | 
|
| Exposure Routes inhalation, skin absorption, ingestion, skin and/or eye contact | |
| Symptoms Dermatitis; hemorrhagic cystitis; dyspnea (breathing difficulty), ataxia, methemoglobinemia; hematuria (blood in the urine); dysuria; [potential occupational carcinogen] | |
| 
Target Organs 
Bladder, skin  Cancer Site [bladder cancer]  | 
|
| See also: INTRODUCTION See ICSC CARD: 0518 See MEDICAL TESTS: 0153 |